Pharmacology News and Research

Latest Pharmacology News and Research

Interleukin-1 plays major role in wound healing

Anesthesiologists are playing a leading role in research into the molecular factors affecting inflammation, pain, and healing of surgical incisions, as illustrated by papers published in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

7 Dec 2010

PAREXEL International opens two new Clinical Logistics Services facilities

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has opened two new Clinical Logistics Services facilities in emerging regions for biopharmaceutical development. PAREXEL's new depot in Singapore and ancillary warehouse in Russia will support its clients in more effectively managing their global clinical trial supply requirements.

From Parexel 6 Dec 2010

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

Today, Lundbeck Inc. presented positive data from its pivotal phase III study to determine the efficacy and safety profiles of the investigational compound clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.

6 Dec 2010

$Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting$

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting held in Orlando, Florida.

6 Dec 2010

Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.

4 Dec 2010

New clues into mechanisms underlying antiphospholipid syndrome

Thanks to findings by UT Southwestern Medical Center researchers, individuals with a potentially life-threatening condition predisposing them to blood clots, or thrombosis, might someday receive therapy to prevent the condition.

4 Dec 2010

Dysfunction in blood vessels plays a role in Alzheimer's disease development

A dysfunction in the lining of blood vessels that is linked to cardiovascular illness also appears to play a role in the development of Alzheimer's disease, according to a study published in Circulation Research: Journal of the American Heart Association.

3 Dec 2010

Advinus collaborates with Corning to bring Epic technology to India

Advinus Therapeutics, the research-based pharmaceutical company promoted by the TATA Group, and Corning Incorporated today announced a collaboration to bring Corning Epic label-free detection technology to India.

2 Dec 2010

Aspirin decreases plaque formations that cause heart attacks and strokes

Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published the results of A Randomized Trial of Aspirin at Clinically Relevant Doses and Nitric Oxide Formation in Humans in the current issue of the Journal of Cardiovascular Pharmacology and Therapeutics.

2 Dec 2010

Lipids react and change to bacterial stimulus, trigger cell's immune response

For the first time, scientists have described not only the identities and quantities of fat species in a living mammalian cell in this case, a mouse macrophage or white blood cell but they also report how these lipids react and change over time to a bacterial stimulus triggering the cell's immune response.

2 Dec 2010

Overexpression of microRNA 125b can cause leukemia: Research

Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).

30 Nov 2010

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies.

30 Nov 2010

DK Sinopharma third quarter sales increase 66% to $7,290,685

DK Sinopharma, Inc., announced its third quarter 2010 financial results. The Company's quarterly report on Form 10-Q was filed with the U.S. Securities & Exchange Commission on November 22, 2010.

29 Nov 2010

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck today reported initial results from the Phase III study investigating the efficacy and safety of a treatment regimen including ISENTRESS® (raltegravir) Tablets once daily in treatment-naïve adult patients infected with HIV-1. ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve and treatment-experienced adults.

29 Nov 2010

Evotec to collaborate with Merck on neurological disease drug discovery program

Evotec AG today announced that it has signed within the "NEU²-Consortium" framework and partially funded by the Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung - BMBF), an agreement with Merck KGaA, Darmstadt, Germany, to develop pre-clinical candidates for an undisclosed neurological disease. Evotec will provide drug discovery expertise covering in vitro biology, medicinal chemistry and in vitro and in vivo pharmacology.

23 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

New editorial dispel doubts about Lou Gehrig's ALS diagnosis

A recent study suggesting that amyotrophic lateral sclerosis (ALS) may be attributed to repetitive head trauma experienced in collision sports lacks scientific epidemiological evidence to support this claim.

20 Nov 2010

Harvard researcher to receive 2010 Naomi Berrie Award from Columbia University Medical Center

Columbia University Medical Center will present the 2010 Naomi Berrie Award to a Harvard researcher who has made important advances in understanding the molecular basis for links between obesity, diabetes and heart disease. A promising young investigator at Columbia will also be recognized for her novel investigations regarding the basis for disordered lipid metabolism in diabetes.

20 Nov 2010

Merck wins third FOSAMAX bellwether trial

Merck & Co., Inc. today said a federal court jury in New York found in its favor in the Graves v. Merck case, rejecting the claims of a Florida woman who blamed her dental and jaw related problems on her FOSAMAX use. With today's verdict, Merck has won three of the first four bellwether cases in the FOSAMAX litigation.

20 Nov 2010

Researchers document novel form of splicing in nerve cell cytoplasm

Cells have their own version of the cut-and-paste editing function called splicing. Researchers at the University of Pennsylvania School of Medicine have documented a novel form of splicing in the cytoplasm of a nerve cell, which dictates a special form of a potassium channel protein in the outer membrane.

19 Nov 2010